ascopubs.org

A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy compared to synthetic control cohort: Results ...

Clinical validation of Histotype Px Colorectal in patients in a U.S. colon cancer cohort. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full ...
ascopubs.org

A phase 2 trial of TAS-102 with or without celecoxib in ctDNA-defined minimal residual disease (MRD) in colorectal cancer after completion of adjuvant chemotherapy.

Phase II trial of adjuvant toripalimab in stage IIb, IIc, or III colon cancer with mismatch repair deficiency. Reducing the resection range after neoadjuvant therapy for locally advanced upper rectal ...